With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
ZBH — frequently asked questions
Is Zimmer Biomet Holdings, Inc. overvalued?
In our latest published analysis dated 2026-10-11, ZBH looks meaningfully undervalued. The price recorded at analysis is USD 89.1 versus our fair value of USD 120; the high endpoint is presented separately as potential value of USD 186. That implies roughly 34.2% upside to fair value at that date.
Our latest published report, analyzed 2026-10-11, gives ZBH a fair value of USD 120 and a potential value of USD 186. The conclusion is triangulated across multiple valuation models and weighted by reliability for Zimmer Biomet Holdings, Inc.'s archetype; it is a dated research output, not a live price.
Should I buy ZBH now?
Our latest published rating for ZBH, analyzed 2026-10-11, is Strong Buy. Zimmer Biomet Holdings, Inc. looks meaningfully undervalued at the analysis-date price of USD 89.1 versus fair value of USD 120; potential value is USD 186. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for ZBH?
The dedicated bear-case section in our report analyzed 2026-10-11 documents Zimmer Biomet Holdings, Inc.'s material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is ZBH's rating?
Our latest published rating for ZBH, analyzed 2026-10-11, is Strong Buy, with a published moat assessment of 7.5/10 (Narrow). It reflects our fair value of USD 120, the potential value of USD 186, and the price recorded at analysis (USD 89.1).
The biggest opportunity lies in accelerated hospital and ASC adoption of the ROSA surgical robotics ecosystem—where H1 2026 procedure volume matched full-year 2025 —paired with high-margin international launches like iodine-coated hips in Japan commanding ~40% price premiums.
Main risk
Annual realized pricing pressure exceeding 100 basis points driven by Medicare CJR-X bundle cuts and proposed Physician Fee Schedule reductions.
Zimmer Biomet Holdings Inc. (ZBH) is assigned a Strong Buy rating with an intrinsic Fair value of $119.59, offering 34.16% upside (25.46% price discount) from the share price of $89.14 as of October 9, 2026. The market overpenalizes transitory commercial salesforce restructuring friction while ignoring entrenched surgeon switching costs in core knee reconstruction, durable ~71% gross margins, and accelerating surgical robotics utilization.4,5
At $89.14 as of October 9, 2026, Zimmer Biomet trades at 10.05x forward earnings, a wide valuation discount to medtech peers such as Boston Scientific at 12.65x and Steris at 17.51x. This compression reflects investor caution regarding a three-stage commercial salesforce reorganization scheduled through year-end 2027, which contracts FY2026 operating margins by a little more than 50 basis points alongside ongoing procedural pricing pressure of 80 to 100 basis points.3,4,5
However, the underlying fundamentals of the business remain exceptionally robust. Core Product Knees generated $3,322.3M or 40.4% of FY2025 net sales ($8,231.5M). High surgeon switching costs protect this procedural base, while hospital wait times hold steady at 3 to 6 months. Furthermore, surgical robotics momentum is accelerating: procedure volumes on the ROSA platform in H1 2026 equaled full-year 2025 volume, locking in long-term consumable implant pull-through. In addition, international rollouts such as first-to-world iodine-coated hips in Japan command ~40% price premiums, helping offset domestic pricing headwinds.5,6,7
Cash conversion provides a powerful shareholder return engine. Low annual capital expenditures of $224.5M (2.7% of revenue in FY2025) relative to D&A of $1,093.8M allow the company to fund up to $1.0 billion in share repurchases in FY2026. This repurchasing power dwarfs stock-based compensation of $90.2M, reducing diluted share count by ~1.5% and driving EPS accretion from $8.53 in FY2026 to $9.07 in FY2027. Intrinsic Fair value of $119.59 represents a compelling opportunity to own a market leader at a deep cyclical discount.1,5,6
Deep Valuation Disconnect Against Medtech Peers
Trading at 10.05x forward P/E, ZBH sits at a meaningful discount to medtech peers BSX (12.65x) and STE (17.51x), creating 34.16% upside to Fair value of $119.59.3,4
Surging Surgical Robotics Adoption
H1 2026 ROSA robotic procedure cases equaled full-year 2025 volume, driving implant pull-through across knees, hips, and shoulders.5
Substantial Capital Return and Share Reduction
Planned capital return of up to $1.0 billion in share repurchases outpaces stock-based compensation of $90.2M, reducing share count and boosting EPS accretion.
House recommendation
Strong Buy. Zimmer Biomet is a mispriced mature compounder trading at 10.05x forward P/E, offering a 25.46% discount and 34.16% upside to our intrinsic Fair value of $119.59. The market overweights transitory commercial salesforce restructuring costs while underappreciating durable surgeon switching costs, ~71% gross margins, and rapid ROSA robotics adoption.4,5
Company overview
Zimmer Biomet Holdings Inc. is a global medical technology leader specializing in musculoskeletal healthcare. The company designs, manufactures, and markets orthopedic reconstructive products, including knee and hip implants, sports medicine, biologics, foot and ankle products, trauma products, and surgical technologies. In FY2025, consolidated revenue reached $8,231.5M, led by Product Knees at $3,322.3M (40.4%), Product Hips at $2,093.5M (25.4%), and S.E.T. products at $2,150.2M (26.1%).
Geographically, the business serves healthcare providers across the Americas ($5,144.6M, 62.5% of FY2025 revenue), EMEA ($1,828.8M, 22.2%), and Asia Pacific ($1,258.1M, 15.3%). Its customer base spans hospital inpatient systems and rapidly growing ambulatory surgical centers, supported by integrated surgical technologies including the ROSA robotics suite.
In a severe downside stress scenario combining an acceleration of pricing erosion to 150 basis points, prolonged salesforce turnover that contracts revenue growth below 1.5%, and debt refinancing at elevated pre-tax rates of 6.39% on $7.52B of total debt, operating margins would fall below 13.0%. Under these compounded pressures, intrinsic value compresses toward the lower valuation bound of $82.17.
Zimmer Biomet possesses a Narrow economic moat grounded in high procedural switching costs, specialized surgical instrumentation, and a growing installed base of ROSA surgical robotics consoles. In orthopedic reconstruction, surgeon brand loyalty is exceptionally durable because training on specific implant geometries and instrumentation kits creates significant operational switching barriers. In FY2025, Product Knees generated $3,322.3M or 40.4% of consolidated net sales of $8,231.5M, representing an entrenched franchise that competitors cannot easily displace.
The moat is further reinforced by surgical robotics integration. Robotic procedure volume on the ROSA platform in the first half of 2026 matched the entirety of FY2025 case volume. Because robotic console placements tie surgical workflows, pre-operative planning, and intra-operative navigation to Zimmer Biomet's proprietary implants, hospital systems face high friction when contemplating alternative suppliers. However, the moat is constrained to Narrow rather than Wide due to structural reimbursement headwinds: annual realized pricing faces an 80 to 100 bps drag, preventing the business from extracting unconstrained economic rents.
Zimmer Biomet's economic profit durability is anchored by of approximately 71% and generation. While GAAP has been compressed by past acquisition and transitional commercial reorganization expenses (contracting FY2026 by >50 bps), the core business generates cash returns above its moderate of 8.0816% and of 7.3575%. Modest requirements ($224.5M in FY2025, or 2.7% of ) support conversion that funds up to $1.0 billion in share repurchases.
The highlighted cell is Fair value when every assumption sits at its base level ($119.59). Each row and column shows what Fair value becomes when one assumption moves.
Free cash flow to the firm stays positive in the first projected year at $778.9M after modeled reinvestment of $137.5M, with terminal value at 83.1% of enterprise value. A sudden drop in free cash flow is not projected unless capital spending relative to , reinvestment, or resets materially.
Revenue and earnings exceeding the high end of management guidance confirm that commercial restructuring is accelerating surgical robotic share gains without representative disruption.
In-line
Maintain Strong Buy; Maintain position weighting and monitor salesforce turnover metrics alongside gross margin stability.
Medical device industry benchmarks show capex-to-revenue of 4.5% and capex-to-depreciation of 0.8x as of 2026-10-05, compared to Zimmer Biomet's FY2025 capex of $224.5M (2.7% of $8,231.5M revenue). Because specific data on industrial capacity utilization, order backlogs, component lead times, and customer concentration are unavailable, the industry cycle assessment is demand-led and evidence-limited.6
Bull cycle
In a bull cycle scenario, surgical backlogs clear rapidly as hospital staffing normalizes, wait times contract from 3 to 6 months, ambulatory surgical center migration accelerates procedure volume, and international demand for premium technologies such as iodine-coated hips in Japan (commanding 40% premiums) expands procedural volumes above 5% annually.
Bear cycle
In a bear cycle scenario, persistent healthcare system margin pressure and regulatory reimbursement cuts (such as Medicare CJR-X bundle reductions) exacerbate procedural pricing headwinds beyond 100 bps, while hospital capital spending constraints slow robotic console acquisitions.
§11 Position management
Sizing
4-6%
A 4-6% portfolio allocation reflects high conviction in the durable clinical switching costs protecting the core knee franchise ($3,322.3M or 40.4% of FY2025 revenue), ~71% gross margins, and a depressed valuation multiple of 10.05x forward P/E that offers substantial margin of safety to fair value of $119.59.4,5,7
Risk
§12 Investor perspectives
Value Investor
Buy
Zimmer Biomet trades at an undemanding forward P/E of 10.05x, representing a significant discount to peers BSX (12.65x) and STE (17.51x). At $89.14, the stock offers a 25.46% discount to its Fair value of $119.59, underpinned by stable ~71% gross margins and up to $1.0B in share repurchases.3,4,5
Growth & Quality Investor
Buy
Adoption of the ROSA surgical robotics platform is accelerating, with H1 2026 case volumes matching all of FY2025. First-to-world products like iodine-coated hips command 40% premiums in Japan, positioning the company for accelerating EPS growth toward $9.07 in FY2027 as commercial restructuring finishes.1
§14 Final recommendation
Action
Strong Buy
Zimmer Biomet represents a high-conviction Strong Buy with an intrinsic Fair value of $119.59, offering 34.16% upside from the share price of $89.14 as of October 9, 2026. The company's deep clinical moat in large joint reconstruction, sticky surgeon switching costs, and ~71% gross margins protect cash flows while commercial restructuring noise creates an exceptional valuation discount at 10.05x forward P/E.4,5
With up to $1.0 billion in capital return via share repurchases and rapid uptake of ROSA surgical robotics, investors are well-compensated through substantial fundamental cash flow accretion as temporary salesforce transition costs subside by 2027.
§15Your notes
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Private notes
Visible only to you. Synced to this device.
0 chars
Sources
The records this analysis drew on, as they stood when it was run.
In the bear case, persistent procedural pricing headwinds accelerate beyond 100 basis points due to Medicare CJR-X bundle reductions. Commercial salesforce restructuring causes disruption and territory friction through 2027, resulting in account defections to competitors. Constant currency revenue growth slows below management guidance ranges and operating margins remain compressed below 13.0%.
Ways this thesis can break
Reimbursement Cuts and Pricing Headwind Acceleration
Realized pricing currently represents an 80 to 100 bps annual headwind. If Medicare CJR-X bundle cuts and proposed 2027 Physician Fee Schedule reductions accelerate net pricing erosion, operating margin would drop below 13.0%, impairing operating income.5
FV impact
-4.6%
Operating margin 3 points lower throughout
Trigger
Within 12 months
Commercial Salesforce Disruption and Orthopedic Account Defection
Management's commercial reorganization spans three stages through the end of 2027. If representative turnover leads to surgeon disruption and competitive account losses to Stryker or J&J, constant currency revenue growth would fall below 1.5% YoY compared to management's organic guidance of 2.25%-3.25%.5
FV impact
-6.5%
Revenue and EPS growth 5 points lower for five years
ZBH currently trades at 10.05x forward P/E, a discount to peer BSX at 12.65x and STE at 17.51x. If restructuring stumbles persist, the exit multiple compresses to 10.0x-10.5x rather than expanding to the modeled 13.5x.3,4
FV impact
-5.1%
Terminal multiple 20% lower
Trigger
Within 24 months
Refinancing Cost Surge and Macro Capital Cost Escalation
ZBH carries $7.52B in total debt, requiring sustained cash conversion and working capital discipline to service leverage. An increase in WACC by 100 bps from 7.3575% to 8.36% driven by debt refinancing at pre-tax rates of 6.39% depresses enterprise fair value.2,4
FV impact
-11.9%
Cost of capital 1 point higher
Trigger
Within 12 months
Early-warning signals to monitor
The five developments that would weaken our investment case.
01
Realized Net Pricing Headwind
Pricing degradation beyond 150 bps indicates payer cuts and hospital purchasing resistance are overwhelming implant innovation, directly compressing gross margins below the 71% threshold.
Current:80 bps headwind in Q2 2026, guided up to 100 bps annual pressure
Alert if> 150 bps annual headwind for two consecutive quarters
Growth falling below 1.5% signals that the commercial salesforce restructuring is causing territory disruption and defection of key orthopedic surgeon accounts to competitors.
Negative APAC growth would prove that China volume-based procurement pressure and tender delays are neutralizing the premium pricing gains achieved in Japan.
01High Surgeon Switching Costs and Specialized Instrumentation — Surgeons develop intense muscle memory and workflow familiarity with proprietary Zimmer Biomet instrumentation kits and surgical techniques. Orthopedic procedures require specialized trays and instrumentation, creating steep switching costs that protect the knee reconstruction revenue base of $3,322.3M (40.4% of FY2025 net sales).Wide
02Surgical Robotics Installed Base and Ecosystem Integration — Placement of the ROSA surgical robotics platform, ROSA Shoulder, ROSA OptimiZe, and handheld devices integrates proprietary software, pre-operative planning, and implant geometry into the hospital operating room. H1 2026 robotic procedure cases equaled the entirety of FY2025, locking in consumable implant pull-through.Moderate
03Proprietary Intangible Assets and Differentiated Surface Technologies — Patented material science innovations such as Trabecular Metal and first-to-world iodine-coated hip implants in Japan command ~40% price premiums by addressing periprosthetic joint infection risks, supported by extensive clinical registry data and regulatory clearances.Moderate
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and at , then adjust for signed per current share.
Terminal exit multiple in line with historical valuation levels
Under the base case, Zimmer Biomet executes its commercial reorganization across three stages through 2027, stabilizing domestic knee and hip market share while ROSA robotics placements expand procedural volume. FY2026 reported revenue grows 4.43% to $8,596.2M, and FY2027 revenue reaches $8,904.5M. Operating margins trough at 13.0% in FY2026 before expanding to 14.0% in FY2027 and 16.0% by FY2030. Diluted EPS expands from $8.53 in FY2026 to $9.07 in FY2027, supported by share repurchases of up to $1.0B.1,5
In the bull case, rapid ROSA surgical robotics placement drives accelerating market share gains in knees and shoulders, while international launches of first-to-world iodine-coated hips in Japan achieve rapid market conversion at 40% premiums. Salesforce specialization concludes ahead of schedule with negligible turnover. Revenue growth accelerates to 5.0% and operating margins reach 17.0%, propelling intrinsic value toward $185.55.5
Earnings quality is supported by stable GAAP gross margins near 71% and strong cash generation. In FY2025, operating cash flow stood well above net income of $705.1M, driven by non-cash depreciation and amortization of $1,093.8M. For the six months ended June 30, 2026, operating cash flow reached $807.2M against depreciation of $540.8M. Stock-based compensation of $90.2M in FY2025 represents a low 1.1% of revenue, well below medtech industry averages (2.1%), indicating minimal non-cash compensation dilution.5,6
Estimate momentum
Consensus revisions remained flat immediately following the Q2 2026 earnings release, reflecting management's measured guidance philosophy to 'say less and do more'. FY2026 consensus EPS remained unchanged at $8.47 immediately post-event, and FY2027 consensus EPS held at $9.00. Subsequent consensus snapshots have drifted modestly upward to $8.53 for FY2026 and $9.07 for FY2027, aligned with the raised guidance range of $8.47 to $8.59.1,5
Management pursues a balanced capital allocation strategy prioritizing tuck-in M&A and share repurchases. Capital returns in FY2026 target up to $1.0 billion in share repurchases, which comfortably exceeds annual stock-based compensation of $90.2M. Total debt stands at $7,519.1M as of year-end FY2025 ($7,601.7M total debt input in cost of capital), with long-term debt of $6,932.0M reported as of June 30, 2026. Management has maintained a disciplined acquisition envelope of up to $2.0 billion for targets that are revenue-accretive, EPS-accretive by year two, and exceed double-digit ROIC by year five.
Historical GAAP ROIC has been weighed down by the large intangible asset base from the Biomet merger and transitory restructuring charges. However, as the three-stage commercial salesforce reorganization concludes by the end of FY2027, operating margins are projected to expand from 13.0% in FY2026 to 16.0% in FY2030, driving operating profit and economic value added above capital costs.
Third-party models estimate current ROIC at 5.49% as of 2026-10-11, which temporarily sits below the moderate cost of equity of 8.0816% and WACC of 7.3575%, but cash return on invested capital expands as commercial reorganization completes.
Commercial Restructuring Depresses FY2026 Margins Before Unlocking Leverage
Management guidance anticipates operating margin contraction of a little more than 50 basis points in FY2026 due to dedicated salesforce investments and Paragon 28 dilution.
FY2026 represents the trough operating margin (13.0%), providing an attractive entry point before margins expand toward 14.0% in FY2027 and 16.0% by FY2030.
Zimmer Biomet Holdings Inc. (ZBH) trades at 10.1x forward earnings against a peer median of 15.1x. Its EV/EBITDA of 9.5x compares with a peer median of 13.2x. The comparison uses 4 peers: STERIS plc, GE HealthCare Technologies Inc., DexCom Inc. and Boston Scientific Corporation, as of 2026-10-11.
Secular trends
Trend
Impact
Note
Aging Global Demographics and Joint Wear
positive
An expanding population aged 65 and older drives steady secular growth in total knee and hip arthroplasty procedures, supported by long hospital waiting lists of 3 to 6 months.
Shift to Ambulatory Surgical Centers (ASCs)
positive
Surgeons increasingly perform outpatient joint reconstructions in ASCs, where implants represent 14% to 15% of total procedure costs, creating strong demand for compact surgical robotics like ROSA OptimiZe and handheld tools.
Healthcare Payer Reimbursement Compression
negative
Government programs like Medicare CJR-X and bundled payments create persistent 80 to 100 bps annual pricing headwinds, requiring implant manufacturers to offer differentiated technology to defend realization.
Positioning
Zimmer Biomet is strongly positioned within the orthopedic cycle as the co-market leader in large joints, generating $3,322.3M in Knees (40.4% of FY2025 revenue) and $2,093.5M in Hips (25.4%). Its comprehensive technology suite—spanning ROSA robotics, ROSA Shoulder, and mixed-reality navigation —positions the company to capture outpatient ASC market share while maintaining gross margins around 71%.5,7
Risk management centers on monitoring commercial reorganization milestones and reimbursement shifts. The position size is capped at 6.0% of portfolio equity to manage exposure to medtech regulatory and policy changes. Downside risk is managed through quarterly fundamental audits of surgeon retention and gross margin thresholds rather than mechanical price stop-outs, preserving exposure to the company's substantial free cash flow yield and up to $1.0 billion capital return program.
Entry tranches
Level
Action
Why
$88.00 - $90.00
Initiate 60% of target position
The share price of $89.14 as of October 9, 2026 offers an attractive 25.46% discount to fair value of $119.59 and a 10.05x forward P/E.
$82.00 - $85.00
Deploy remaining 40% of target position
Add aggressively if market volatility drives shares toward the conservative cash flow floor, providing exceptional asymmetric upside.
Exit tranches
Level
Action
$118.00 - $120.00
Trim 30% of position upon convergence with house Fair value ($119.59)
$140.00 - $150.00
Trim an additional 30% as valuation expands toward historical median medtech peer multiples
Downside risks center on persistent 80 to 100 bps annual pricing erosion compounded by potential surgeon disruption during the three-stage commercial salesforce reorganization extending through 2027. If representative turnover leads to defections of high-volume orthopedic surgical accounts to rivals, organic revenue growth would fail to reach the guided 2.25%-3.25% range, capping operating margin recovery.5
Data covering 2025-12-31 to 2026-10-11 · cited for 4 figures
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
Discounted forecast-period cash flows ($19.79) plus discounted terminal value ($96.99) minus signed net debt per current share ($36.32) equals the $80.46 lens value shown above. Negative net debt is net cash, so subtracting it raises value.
